|Positive Phase II Study of Pacira’s EXPAREL™ (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)|
Novel Local Analgesic Results in Sustained Plasma Concentrations Significantly Reducing Postoperative Pain
Parsippany, NJ, Dec. 14, 2008 - A Phase II trial of a single intraoperative administration of EXPAREL (DepoBupivacaine) resulted in significantly reduced pain with activity in the first 8 to 24 hours following surgery, when pain is generally greatest, compared to conventional treatment. The results of the multicenter, randomized, double-blind study were presented in a poster at the Annual Postgraduate Assembly in Anesthesiology in New York City today, by lead investigator Richard Langford, MD, FRCA, Pain and Anaesthesia Research Centre, St. Bartholomew’s Hospital, London, UK.
Dr. Langford indicated that EXPAREL provided safe and well-tolerated analgesia with normal wound healing in all patients and noted that the study also showed:
In addition, the study demonstrated dose-proportional sustained plasma concentrations which support the prolonged local release of bupivacaine.
Presenting the results, Dr. Langford stated, “In addition to significantly lowering pain scores with activity during the 8 to 24 hours after administration, EXPAREL also showed trends of decrease in the number of patients using opioids and a decrease in total opioid consumption. This is an important finding as lowering opioid usage can spare patients from side effects, such as sedation, nausea, vomiting and respiratory depression, that can adversely affect their recovery.”
EXPAREL, a proprietary product of Pacira Pharmaceuticals, Inc., is a novel long-acting,sustained-release formulation of bupivacaine HCL, a local anesthetic widely used for treating postoperative pain. The dose-escalating study evaluated the efficacy, safety, and pharmacokinetics of EXPAREL compared to bupivacaine HCL in 76 adult male patients (age ranges 48 to 63) in 10 hospitals in the UK and Australia. Subjects were randomized into one of four cohorts and intraoperatively administered either 175mg, 225mg, 300mg or 325mg of EXPAREL or 100mg bupivacaine HCL around the surgical wound by infiltration immediately before closure.
Safety assessments reported in the poster found EXPAREL to be safe and well-tolerated. Wound healing was normal in all EXPAREL subjects with no significant differences between cohorts. Adverse events were generally mild to moderate with no significant differences between cohorts and no serious adverse events were attributed to the study drug.
Inguinal hernia repair is one of the most common operations in routine surgical practice. In the U.S., more than 600,000 procedures are performed annually with a majority performed on an out-patient basis, according to the National Center for Health Statistics.
The Potential of EXPAREL
“The anesthesiology and surgical community recognizes the need for new approaches to postoperative pain management and welcomes the potential advance EXPAREL presents in overcoming limitations of conventional bupivacaine formulations,” said Ronald Burch, M.D, PhD, Chief Medical Officer, Pacira. “EXPAREL, currently in late Phase III clinical development, is being studied in several different types of surgical procedures where postoperative pain management is especially problematic and where the need for prolonged analgesia via a single administration can provide a significant improvement in pain relief, especially during the first 72-hours following surgery when pain is the most intense.”
EXPAREL is the latest product to benefit from Pacira's proprietary sustained-release DepoFoam® technology. DepoFoam technology is designed to address the limitations of widely used medications by enhancing their dosing and/or administration profile. It achieves this by encapsulating the drug in multivesicular liposomal particles which then release the drug over a desired period of time without altering the drug molecule. DepoFoam is a proven technology that is already used in two commercially available products in the U.S. and Europe.
This news release and the anticipated presentation contain forward-looking statements that involve risks and uncertainties, including statements relating to initiation and progress of the Company's clinical trial programs and the preliminary results from the clinical trials. Actual results could differ materially from those projected and the Company cautions readers not to place undue reliance on the forward-looking statements contained in the release and anticipated presentation.